SHADY G. EL-SAWAH1,*, FAYEZ ALTHOBAITI2, HANAN M. RASHWAN1, ADIL ALDHAHRANI3, MARWA A. ABDEL-DAYEM4, EMAN FAYAD2, REHAB M. AMEN5, EL SHAIMAA SHABANA6, EHAB I. EL-HALLOUS7
BIOCELL, Vol.46, No.3, pp. 745-757, 2022, DOI:10.32604/biocell.2022.017853
- 18 November 2021
Abstract Since Type 1 diabetes (T1DM) occurs when β-cells mass is reduced to less than 20% of the normal level due to autoimmune destruction of cells resulting in the inability to secrete insulin, preservation or replenishment of the functional β-cells mass has become a major therapeutic focus for this diabetic type treatment. Thus, this 4-week work plan was designed to determine which mesenchymal stem cells (MSCs) type is more appropriate to alleviate pancreatic hazards resulting from diabetes induction; via tracking a comparative study between MSCs derived from adipose tissue (AD-MSCs) and from bone marrow (BM-MSCs) in… More >